Synthesis of a norcantharidin-tethered guanosine: Protein phosphatase-1 inhibitors that change alternative splicing

  • Stefan Kwiatkowski
  • , Vitaliy M. Sviripa
  • , Zhaiyi Zhang
  • , Alison E. Wendlandt
  • , Claudia Höbartner
  • , David S. Watt
  • , Stefan Stamm

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Phosphorylation and dephosphorylation of splicing factors play a key role in pre-mRNA splicing events, and cantharidin and norcantharidin analogs inhibit protein phosphatase-1 (PP1) and change alternative pre-mRNA splicing. Targeted inhibitors capable of selectively inhibiting PP-1 could promote exon 7 inclusion in the survival-of-motorneuron-2 gene (SMN2) and shift the proportion of SMN2 protein from a dysfunctional to a functional form. As a prelude to the development of norcantharidin-tethered oligonucleotide inhibitors, the synthesis a norcantharidin-tethered guanosine was developed in which a suitable tether prevented the undesired cyclization of norcantharidin monoamides to imides and possessed a secondary amine terminus suited to the synthesis of oligonucleotides analogs. Application of this methodology led to the synthesis of a diastereomeric mixture of norcantharidin-tethered guanosines, namely bisammonium (1R,2S,3R,4S)- and (1S,2R,3S,4R)-3-((4-(2-(((((2R,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-yl)oxy)oxidophosphoryl)oxy)ethyl)-phenethyl)(methyl)carbamoyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylate, which showed activity in an assay for SMN2 pre-mRNA splicing.

Original languageEnglish
Pages (from-to)965-968
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume26
Issue number3
DOIs
StatePublished - 2016

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.

Funding

S.S. and D.S.W. were supported by Muscular Dystrophy Association – United States (MDA grant #135035 ). Research reported in this publication was also supported by the Office of the Dean of the College of Medicine and an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health – United States under grant number NIH P30GM110787 to L. Hersh, P.I. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or the NIGMS.

FundersFunder number
National Institutes of Health (NIH)
National Institute of General Medical SciencesP30GM110787
Muscular Dystrophy Association135035

    Keywords

    • Alternative pre-mRNA splicing
    • Exon 7 inclusion
    • Norcantharidin analogs
    • Protein phosphatase-1 (PP1) inhibitors
    • SMN2 protein

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Medicine
    • Molecular Biology
    • Pharmaceutical Science
    • Drug Discovery
    • Clinical Biochemistry
    • Organic Chemistry

    Fingerprint

    Dive into the research topics of 'Synthesis of a norcantharidin-tethered guanosine: Protein phosphatase-1 inhibitors that change alternative splicing'. Together they form a unique fingerprint.

    Cite this